SecBot SecBot
Biotech Drug Report Generated Nov 18, 2026

CyPath Lung

BIAF·bioAffinity Technologies, Inc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Commercially Available (LDT)
Time to market
Already commercially available in the U.S. as a laboratory developed test (LDT) through the company's CLIA-certified lab. CMS reimbursement has been in effect since January 2024.
Why 4/10
CyPath Lung is already commercially available and generating revenue with no pending FDA PDUFA, pivotal readout, or other hard binary catalyst in the next 12 months. The defining regulatory binary (CMS reimbursement determination) passed in early 2024. ImpactScore is capped at 4 per the rubric for an approved/marketed product with no imminent regulatory decision.
Actionable Insight NEUTRAL

CyPath Lung is already commercial and generating revenue, so the next catalysts are commercial execution metrics (quarterly sales growth, test volumes, physician adoption) and data readouts from the large-scale longitudinal clinical study initiated in March 2026. The stock has fallen ~90% from its 52-week high and recently dipped after Q3 earnings, making sustained sales acceleration the key swing factor for the shares.

Price Chart

Loading chart...

Executive Summary

CyPath Lung is a noninvasive, sputum-based diagnostic test for early-stage lung cancer, developed and commercialized by bioAffinity Technologies (Nasdaq: BIAF). The test uses flow cytometry and an AI algorithm to detect cancer cells in a patient's sputum sample and is offered as a laboratory developed test (LDT) through the company's CLIA-certified lab. It has been commercially available since at least 2023 with CMS Medicare reimbursement in place since January 2024. The company reported Q3 2026 revenue of $1.07 million from the test, with sales more than doubling year-over-year through the first three quarters of 2026. The stock trades near $1.90, down roughly 90% from its 52-week high, and the company recently completed a $4 million direct offering to fund working capital and sales growth.

How It Works

CyPath Lung is a noninvasive diagnostic test that analyzes a patient's sputum (phlegm) sample using flow cytometry and an artificial intelligence algorithm. The test looks for abnormal cells that may indicate lung cancer. Because it only requires a sputum sample rather than a tissue biopsy or blood draw, it is less invasive than many alternatives. The test is run in the company's own CLIA-certified laboratory as a laboratory developed test (LDT).

Trial Status

CyPath Lung is commercially available and generating revenue. A large-scale longitudinal clinical study was initiated in March 2026 to further validate the test. The company is also advancing the test for lung cancer survivor surveillance and exploring applications in asthma and COPD diagnosis.

The Two-Sided Case

▲ Bull Case6
CyPath Lung is a noninvasive, sputum-based test with strong published performance (92% sensitivity, 87% specificity, 88% accuracy) for early-stage lung cancer detection.
Commercial momentum is accelerating: sales more than doubled through Q3 2026 year-over-year, with a record 235 tests performed in October 2026.
CMS has a final payment determination in place (effective January 2024), providing a clear Medicare reimbursement pathway.
The company signed a distribution agreement with AvMEDICAL for the U.S. federal government healthcare market, expanding access to veterans.
Pipeline expansion opportunities exist for lung cancer survivor surveillance and asthma/COPD diagnosis, which could open larger addressable markets.
International patent protection has been secured in Japan, Hong Kong, China, and Canada, strengthening the IP moat.
▼ Bear Case6
Revenue remains tiny ($1.07M in Q3 2026) and the company is unprofitable, requiring repeated capital raises (a $4M direct offering closed in October 2026).
The stock has lost roughly 90% from its 52-week high of $80.70, trading near $1.90, signaling severe market skepticism.
Analyst consensus is weak: 0 buy, 3 hold, 1 sell, 2 strong sell (March 2026 snapshot).
As a laboratory developed test (LDT), CyPath Lung faces regulatory uncertainty if the FDA tightens LDT oversight, potentially requiring a costly premarket review.
Institutional ownership is minimal (largest tracked holder, HRT Financial, holds only $599K), indicating lack of institutional conviction.
Competition in lung cancer screening includes established low-dose CT screening, blood-based liquid biopsy tests (Guardant, Grail/Exact Sciences), and other emerging diagnostics.

Upcoming Catalysts

  • Q4 2026 / full-year 2026 earnings report (expected early 2027) with CyPath Lung sales and test volume updates
  • Data readouts from the large-scale longitudinal clinical study (initiated March 2026)
  • Potential expansion into lung cancer survivor surveillance indication
  • Further distribution expansion through the AvMEDICAL federal healthcare partnership

Source Filing

The SecBot filing or press-release report that triggered this drug report:

bioAffinity Technologies, Inc. 8-K BIAF ·Originating report

Sources · 14

Hover a chip for the title
1 businesswire.com2 businesswire.com3 mpo-mag.com4 mpo-mag.com5 morningstar.com6 streetinsider.com7 rttnews.com8 streetinsider.com9 businesswire.com10 msn.com11 businesswire.com12 businesswire.com13 businesswire.com14 marketscreener.com